Low Sodium Oxybate in Patients With Idiopathic Hypersomnia

Purpose

Low sodium oxybate has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic hypersomnia. In this study, the researchers want to learn how low sodium oxybate impacts ability of people diagnosed with idiopathic hypersomnia to sleep for long periods of time. In addition, this study will use novel tools to determine when an individual is awake or asleep.

Condition

  • Idiopathic Hypersomnia

Eligibility

Eligible Ages
Between 18 Years and 65 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Primary diagnosis of IH, according to ICSD-3 criteria (does not require MSLT) 2. Subjects aged 18 - 65 years 3. BMI between 18 and 35 kg/m2 4. Self-reported sleep duration ≥ 9 hours most days including daytime naps/sleep based upon at least 10/14 days of completed sleep diary entries 5. Epworth Sleepiness Scale (ESS) ≥ 10 (required at pre-screening visit only) 6. Recommended LSO by a clinical sleep specialist as part of routine medical care. The clinical sleep specialist will be responsible for titrating LSO according to standard of care. 7. Subject must be willing to postpone LSO therapy until all baseline assessments completed 8. If treated with wake promoting agents, traditional stimulants and/or antidepressant(s), a stable dose and regimen will be required for at least 2 months before study entry and throughout the main study 9. Have used a medically acceptable method of contraception for at least 2 full menstrual cycles before participating in this study and consent to use a medically acceptable method of contraception from the first dose of study drug, throughout the entire study period, and for 30 days after the last dose of study drug.

Exclusion Criteria

  1. Succinic semialdehyde dehydrogenase deficiency, porphyria 2. Other central nervous system diseases: neurodegenerative diseases, , seizure disorders or history of head trauma associated with loss of consciousness 3. Lifetime history of suicide attempt or suicidal ideation in the past six months, including answer to question #9 on PHQ-9 ≥1; PHQ-9 total score > 10; prior history of psychotic episodes; active major depressive disorder 4. Change to psychiatric medication(s)/stimulant(s) within last 3 months 5. History of chronic alcohol or drug abuse within the prior 12 months 6. Malignant neoplastic disease requiring therapy within the prior 12 months 7. Heart failure, severe hypertension or other cardiovascular disease compromising the patient's well-being or ability to participate in this study 8. Renal or hepatic impairment 9. Compromised respiratory function (e.g., history of COPD, pulmonary hypertension, and/or poorly controlled asthma) 10. Diagnosis of sleep-related breathing disorders (AHI ≥ 15 events/h using 4 % AHI) or high suspicion for sleep disordered breathing 11. Any sleep apnea treatment (e.g., Positive Airway Pressure (PAP) therapy, oral appliance therapy, etc.) 12. No regular sleep at night: shift work or other continuous, non-disease-related life conditions 13. Participation in another study of an investigational drug within the 28 days prior to Screening visit or currently 14. Pregnant and/or breast-feeding 15. Ear jewelry and/or piercings that subject not willing to/unable to remove 16. Use of device/implant that may interfere with the study devices/procedures (e.g., vagal nerve stimulator) 17. Smoke and/or use of smokeless tobacco products 18. Subjects who, in the opinion of the investigator(s), may not be suitable for the study

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Low Soduim Oxybate for Idiopathic Hypersomnia 		Subjects prescribed with low sodium oxybate for idopathic hypersomnia will have a 24-hour polysomnography, wear an Axivity wristband and Nextsense EEG earbuds to evaluate total sleep time.
  • Drug: Low Sodium Oxybate
    Titrated according to standard of care and continued on stable dose for 3 months
    Other names:
    • Xywav
    • Calcium, Magnesium, Potassium, and Sodium Oxybates
  • Diagnostic Test: 24-hour polysomnography
    Performed in a sleep study lab, recording of body functions including brain activity, eye movements, muscle activity, heart rhythm and blood oxygen levels while asleep and awake for a 24-hour period
  • Device: Nextsense EEG earbuds
    Ear buds used to record sleep staging worn for a 24-hours period
  • Device: Axivity device
    Wristband that records activity level worn for approximately one month to track sleep and steps/activity.

Recruiting Locations

Mayo Clinic Arizona
Phoenix 5308655, Arizona 5551752 85054
Contact:
Lupe (Ray) Canez
(480) 574-2753
Canez.Lupe@mayo.edu

Stanford University
Redwood City 5386834, California 5332921 94063
Contact:
Miran Cho
(650)503-3489
mirancho@stanford.edu

Mayo Clinic Florida
Jacksonville 4160021, Florida 4155751 32224
Contact:
Wesley Dillinger
(904)953-3626
dillinger.wesley@mayo.edu

Beth Israel Deaconess Medical Center
Boston 4930956, Massachusetts 6254926 02215
Contact:
Phoebe Aney
(617) 975-7568
paney@bidmc.harvard.edu

More Details

Status
Recruiting
Sponsor
Mayo Clinic

Study Contact

Gabbi Montefiore
(480)574-1288
montefiore.gabrielle@mayo.edu